Abstract

Despite efforts to promote development of therapies for rare diseases, the number of available treatments remains low and progress is too slow to have a significant impact on patients. This does not necessarily reflect a lack of interest in rare disease research, and significant efforts have been made toward the development and clinical testing of molecular therapies for these diseases. The intrinsic challenges of understanding the mechanisms underlying rare diseases render the design of efficacious therapies laborious.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call